Clinical trials: Endocrine System Diseases
Diabetes Mellitus, Type 2
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT05086445
- Testing
- LY3502970
- Where
- 5 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Pre Diabetes, Insulin Resistance
Precision Diets for Diabetes Prevention
With this study the investigators want to understand the physiological differences for people developing pre-diabetes and diabetes.
- Conditions
- Pre Diabetes, Insulin Resistance, Diabetes Mellitus, Type 2
- Trial name
- NCT03919877
- Testing
- Dietary, Oral Food Challege
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Stanford University
Diabetes Mellitus
Ease of Use of New Blood Glucose Meter With In-built Insulin Calculator at Home Study
The aim of this study is to evaluate user preference and ease of use of the FreeStyle InsuLinx system, compared to current methodology, when used at home by subjects with diabetes.
- Trial name
- IHUT (NCT01432275)
- Testing
- ADC blood glucose meter, Comparator blood glucose meter, ADC blood glucose meter with insulin calculator active
- Where
- 7 sites in United Kingdom
- Volunteers
- 179 people
- Sponsor
- Abbott Diabetes Care
Type II Diabetes
Measuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice Experiment
In 2012, the FDA Center for Devices and Radiological Health (CDRH) issued guidance to clarify the principal benefit-risk factors FDA considers during the reviews for premarket approval applications and de novo classification…
- Trial name
- NCT02637622
- Testing
- Best-Worst Scaling (Case 2), Discrete Choice Experiment
- Where
- United States
- Volunteers
- 1,103 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) in comparison to exenatide (Byetta®), as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-X (NCT00707031)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Exenatide
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 639 people
- Sponsor
- Sanofi
Colorectal Cancer, Non-small Cell Lung Cancer
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma
- Trial name
- NCT03576131
- Testing
- GEN1029 (HexaBody®-DR5/DR5)
- Where
- 6 sites in United States, Spain and 1 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Pancreatic Cancer
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
The primary objective is to evaluate the efficacy of a combination of cetuximab with systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. The primary endpoint is actuarial one-year survival.
- Trial name
- NCT00338039
- Testing
- Cetuximab, Gemcitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
PreDiabetes, Prediabetic State
Implementation and Evaluation of a Diabetes Prevention Clinical Pathway in Primary Care
Prediabetes is a significant public health problem affecting 88 million U.S. adults. Evidence suggest that the vast majority of people with prediabetes are unaware of having this condition and many are not receiving appropriate…
- Trial name
- NCT05265312
- Testing
- START diabetes prevention clinical pathway
- Where
- United States
- Volunteers
- 1,910 people
- Sponsor
- Johns Hopkins University
Unresectable Pancreatic Cancer
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
This research study is for people who have pancreas cancer for which surgery is not recommended. Potential patients must have already received several months of chemotherapy before they are eligible for this study and there will…
- Trial name
- NCT01972919
- Testing
- Radiation Therapy, Concurrent chemotherapy (Gemcitabine, Capecitabine)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medical College of Wisconsin
Diabetic Foot Infections
Diabetic Foot Infection Antibiotic Study
This is a pilot study to explore the effects of long-course versus short course antibiotics on wound healing in surgically managed diabetic foot infections.
- Trial name
- NCT01539811
- Testing
- Surgical incision and drainage of diabetic foot infection, Short course antibiotics, Long course antibiotics
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Prisma Health-Upstate
Type1 Diabetes
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes
Randomized trial of youth aged 7-<18 years with newly diagnosed stage 3 type 1 diabetes (T1D) to assess the effect of both (1) near-normalization of glucose concentrations achieved through use of a hybrid closed loop (HCL) system…
- Trial name
- CLVer (NCT04233034)
- Testing
- HCL, verapamil 120mg tablet, non-HCL
- Where
- 6 sites in United States
- Volunteers
- 113 people
- Sponsor
- Jaeb Center for Health Research
Diabetes Mellitus, Type 2
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
- Trial name
- NCT01280695
- Testing
- MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone
- Where
- 14 sites in United States
- Volunteers
- 129 people
- Sponsor
- Metabolic Solutions Development Company
Diabetes, Diabetes Mellitus, Type 2
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment…
- Trial name
- NCT00696657
- Testing
- semaglutide, liraglutide
- Where
- 77 sites in Austria, Bulgaria and 12 more
- Volunteers
- 415 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes never treated with…
- Trial name
- BEGIN™ (NCT00982644)
- Testing
- insulin degludec, insulin glargine
- Where
- 187 sites in United States, Austria and 13 more
- Volunteers
- 1,030 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Using Digital Health, Financial Incentives, and Community Health Worker Support to Change Health Behavior
This randomized controlled trial tests how digital health monitoring with financial incentives (DFI) and community health worker (CHW) support may affect how a person manages their diabetes.
- Trial name
- NCT03939793
- Testing
- IMPaCT Community Health Worker, Digital health monitoring with financial incentives, Usual Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Pennsylvania
Pancreatic Cancer
TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
This is an open-label, non-randomized, sequentially enrolling single arm phase II trial to evaluate the activity of TAS-102 in previously treated metastatic and locally advanced unresectable pancreatic cancer after progression…
- Trial name
- NCT02921737
- Testing
- TAS-102
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
Diabetes Mellitus, Diabetes Mellitus, Type 2
A Virtual Cardiometabolic Health Program for African Immigrants: The Afro-DPP Program
A pilot study titled "A Virtual Cardiometabolic Health Program for African Immigrants (The Afro-DPP Program) will be conducted to address the cardiometabolic of community-dwelling African immigrants who have multiple…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, PreDiabetes, Hypertension
- Trial name
- NCT05144737
- Testing
- The Diabetes Prevention Program
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type 2
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus.
- Trial name
- NCT02119819
- Testing
- LY2944876, Exenatide extended-release, Metformin
- Where
- 51 sites in United States, Greece and 4 more
- Volunteers
- 420 people
- Sponsor
- OPKO Health, Inc.
Glaucoma, Diabetic Retinopathy
Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits
Glaucoma is a blinding eye disease increasingly common in older adults, particularly in African Americans, and often diagnosed late in the disease course.
- Conditions
- Glaucoma, Diabetic Retinopathy, Refractive Errors, Cataract
- Trial name
- AL-SIGHT (NCT04328207)
- Testing
- No Financial Incentive, Financial Incentive
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Diabetes
This study is conducted in Africa, Asia, Europe, Japan and South America. The aim of this observational study is to evaluate the incidence of serious adverse reactions (SARs) while using Levemir® (insulin detemir) under normal…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT00659295)
- Testing
- insulin detemir
- Where
- 13 sites in Belgium, Czechia and 11 more
- Volunteers
- 51,170 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.